ArticleResearch square2026
An intraocular oxygenated emulsion suppresses retinal fibrosis by inhibiting hypoxia-driven bioenergetic shifts and mesenchymal transformation.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Fibrosis drives progressive organ dysfunction, yet targeted therapies remain limited. In the eye, proliferative vitreoretinopathy (PVR) is a blinding fibrotic disease without approved medical treatment. Here, single-cell RNA sequencing of human PVR membranes revealed convergent activation of hypoxia-responsive programs across major cell populations. Using a molecular probe, we directly validated spatial and temporal hypoxia in an open-globe injury model that recapitulates traumatic PVR. Intravitreal delivery of a supersaturated oxygen emulsion (SSOE) preserved retinal function while reducing fibrocellular membrane formation and inflammation. Mechanistically, human PVR cells exhibited metabolic shifts toward glycolysis alongside epithelial-mesenchymal transition (EMT). SSOE corrected cellular hypoxia, preserved mitochondrial integrity, suppressed glycolytic shift, and inhibited EMT in human retinal pigment epithelial cells, while reducing spontaneous contractility in primary human PVR cell cultures. Together, these findings identify hypoxia as a critical driver of retinal fibrosis and support localized intraocular oxygenation as a viable therapeutic strategy for preventing fibrotic vision loss.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.